Tags : Exclusive


Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza

Shots: Novartis to receive $355M following the closure of acquisition, which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and strengthens its footprints in the US The companies will initiate a transition period where Novartis will continue to sell Simbrinza and transfer the profit to Alcon. Following the transition period, […]Read More


Eli Lilly Signs an Exclusive License Agreement with SciNeuro to

Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China, Hong Kong, Macau, And Taiwan Alpha-synuclein directed therapies help to […]Read More


Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT

Shots: Sanofi to receive ~$353M including $2.25M up front and remaining as development, regulatory and commercial milestones as well as royalties on WW net sales of programs GBT gets exclusive WW rights to two early-stage research programs in SCD. One program pursues a novel anti-sickling mechanism and the other leverages a new approach to reduce […]Read More

Biotech COVID-19

Sorrento Collaborates with Mount Sinai to Develop Ab Combination for

Shots: The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants The pre-clinical development of Ab combination (IV and intranasal) including Sorrento and Mount Sinai Abs is underway The collaboration follows Sorrento’s efforts to eradicate COVID-19 […]Read More


Takeda to Acquire Maverick for ~$525M

Shots: Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity stake and Maverick debt. The acquisition is expected to finalize in Q1’21 The acquisition will expand Takeda’s I-O portfolio with the addition of two development candidates (MVC-101 & MVC-280) and […]Read More


Exelixis Signs an Exclusive License Agreement with WuXi Biologics to

Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics applications Exelixis leverages WuXi Bio’s integrated technology platforms to develop […]Read More


Onward Signs a Worldwide Exclusive License and Co-Development Agreement with

Shots: Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies Onward get the right to pursue development, manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early clinical program Biomunex is responsible for early preclinical development, while […]Read More


Genentech Signs an Exclusive License Agreement with X-Chem to Discover

Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to compounds derived from the collaboration. Additionally, Genentech get an exclusive […]Read More